[go: up one dir, main page]

WO2004046732A8 - Methods for screening compounds modulating cholesterol flux and uses thereof - Google Patents

Methods for screening compounds modulating cholesterol flux and uses thereof

Info

Publication number
WO2004046732A8
WO2004046732A8 PCT/FR2003/003303 FR0303303W WO2004046732A8 WO 2004046732 A8 WO2004046732 A8 WO 2004046732A8 FR 0303303 W FR0303303 W FR 0303303W WO 2004046732 A8 WO2004046732 A8 WO 2004046732A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
screening compounds
modulating cholesterol
compounds modulating
cholesterol flux
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/003303
Other languages
French (fr)
Other versions
WO2004046732A1 (en
Inventor
Guilhem Larigauderie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Priority to AU2003292347A priority Critical patent/AU2003292347A1/en
Publication of WO2004046732A1 publication Critical patent/WO2004046732A1/en
Publication of WO2004046732A8 publication Critical patent/WO2004046732A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention concerns methods for selecting, identifying or characterizing compounds capable of modulating cholesterol flux which consist in determining modulation of adipophilin activity. The invention also concerns methods for preparing medicines.
PCT/FR2003/003303 2002-11-15 2003-11-05 Methods for screening compounds modulating cholesterol flux and uses thereof Ceased WO2004046732A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003292347A AU2003292347A1 (en) 2002-11-15 2003-11-05 Methods for screening compounds modulating cholesterol flux and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/14345 2002-11-15
FR0214345A FR2847266A1 (en) 2002-11-15 2002-11-15 Selection of compounds that modulate efflux of cholesterol, useful for treating e.g. atherosclerosis, from their ability to modulate activity of adipophilin

Publications (2)

Publication Number Publication Date
WO2004046732A1 WO2004046732A1 (en) 2004-06-03
WO2004046732A8 true WO2004046732A8 (en) 2005-04-07

Family

ID=32187650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/003303 Ceased WO2004046732A1 (en) 2002-11-15 2003-11-05 Methods for screening compounds modulating cholesterol flux and uses thereof

Country Status (3)

Country Link
AU (1) AU2003292347A1 (en)
FR (1) FR2847266A1 (en)
WO (1) WO2004046732A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261760B1 (en) * 1998-03-09 2001-07-17 The Regents Of The University Of California Regulation of the cell cycle by sterols
JP4726302B2 (en) * 1999-03-15 2011-07-20 ユニバーシティ オブ ブリティッシュ コロンビア Methods and reagents for regulating ABC1 polypeptide and cholesterol levels
WO2001035986A2 (en) * 1999-11-16 2001-05-25 Hamilton Civic Hospitals Research Development Inc. Methods and compositions for modulating er-stress-induced cholesterol accumulation

Also Published As

Publication number Publication date
AU2003292347A1 (en) 2004-06-15
FR2847266A1 (en) 2004-05-21
WO2004046732A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2004037159A3 (en) Compounds, compositions and methods for modulating fat metabolism
AU2003293015A1 (en) Microporous materials, methods, and articles for localizing and quantifying analytes
WO2002099048A3 (en) LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
MXPA02005234A (en) Methods for automatically monitoring analyte concentration using minimally invasive devices.
MXPA03004754A (en) Disc cartridge.
WO2004078995A3 (en) Methods of modulating and of identifying agents that modulate intracellular calcium
AU2002252222A1 (en) System for analyzing strategic business decisions
WO2005051178A3 (en) Marker for neuromyelitis optica
WO2004001375A8 (en) Multi-functional product markers and methods for making and using the same
WO2004020458A3 (en) Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
WO2001023412A3 (en) Methods of screening for agents which inhibit aggregation of polypeptides
WO2004048552A3 (en) Modulating immune responses
WO2007094755A3 (en) Compositions and methods for modulating cognitive function
WO2007076174A3 (en) Methods, systems, and apparatus for multi-domain markers
WO2000052194A3 (en) Methods for detecting membrane derived caspase activity and modulators thereof
EP2261256A3 (en) Methods of inhibiting metastasis
AU2003258454A1 (en) Compounds for modulating the glycolosis enzyme complex and/or transaminase complex
WO2005051423A3 (en) Methods and agents for immune modulation and methods for identifying immune modulators
WO2004014319A3 (en) Screening strategy for anticancer drugs
WO2004046732A8 (en) Methods for screening compounds modulating cholesterol flux and uses thereof
WO2006098998A3 (en) Methods and compositions for modulating vascular integrity
AU2002364612A1 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
AU2003253593A1 (en) Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
WO2005055942A3 (en) Modulation of brain pathways and function
WO2002031115A3 (en) Nucleic acid molecules and polypeptides for immune modulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA US

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 23/2004 ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."